Company Profile - Syros Pharmaceuticals Inc

Introduction

Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist, SY-2101, a arsenic trioxide (ATO) and SY-5609, a highly selective and potent oral inhibitor. Syors products are used to treat the patients with acute myeloid leukemia and myelodysplastic syndrome (MDS); acute promyelocytic leukemia, pancreatic cancer and BRAF-mutant colorectal cancer. It also provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. The company’s gene control platform identifies novel gene control targets linked to genomically defined patient populations and drugging gene control targets. It partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US